Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on ...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's received approval. Read why BMY earns a Strong Buy upgrade.

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of ...